New insights on the mechanisms of disease course variability in ALS from mutant SOD1 mouse models

Brain Pathology

Volumn 26, Issue 2, 2016, Pages 237-247

  Nardo, Giovanni ^a   Trolese, Maria Chiara ^a   Tortarolo, Massimo ^a   Vallarola, Antonio ^a   Freschi, Mattia ^a,b   Pasetto, Laura ^a   Bonetto, Valentina ^a   Bendotti, Caterina ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica   (Italy)

Author keywords

biomarkers; disease course variability; motor neuron; peripheral motor system; Transgenic SOD1G93A mice

Indexed keywords

BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; SOD1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DISEASE COURSE; GENETIC BACKGROUND; METABOLISM; MOLECULAR MECHANICS; MOTONEURON; MOUSE; MOUSE MODEL; MSOD1 MOUSE; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; PROGNOSIS; SCIATIC NERVE; SPINAL CORD; TREATMENT RESPONSE; 129 MOUSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; SUPEROXIDE DISMUTASE-1;

EID: 84961833595     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12351     Document Type: Conference Paper

References (106)

1. Ajroud-Driss S, Siddique T, (2015) Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 1852: 679-684.
2. Al-Saif A, Al-Mohanna F, Bohlega S, (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 70: 913-919.
3. Almind K, Kahn CR, (2004) Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes 53: 3274-3285.
4. Averaimo S, Milton RH, Duchen MR, Mazzanti M, (2010) Chloride intracellular channel 1 (CLIC1): sensor and effector during oxidative stress. FEBS Lett 584: 2076-2084.
5. Banci L, Bertini I, Boca M, Girotto S, Martinelli M, Valentine JS, Vieru M, (2008) SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS One 3: e1677.
6. Barrette B, Hebert MA, Filali M, Lafortune K, Vallieres N, Gowing G, et al, (2008) Requirement of myeloid cells for axon regeneration. J Neurosci 28: 9363-9376.
7. Basso M, Samengo G, Nardo G, Massignan T, D'Alessandro G, Tartari S, et al, (2009) Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One 4: e8130.
8. Beghi E, Chio A, Couratier P, Esteban J, Hardiman O, Logroscino G, et al, (2011) The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 12: 1-10.
9. Benatar M, (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26: 1-13.
10. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, Braga M, et al, (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 191: 25-33.
11. Bendotti C, Marino M, Cheroni C, Fontana E, Crippa V, Poletti A, De Biasi S, (2012) Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog Neurobiol 97: 101-126.
12. Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW, (2007) Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 25: 54-64.
13. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, et al, (2009) Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 111: 1182-1191.
14. Caron I, Micotti E, Paladini A, Merlino G, Plebani L, Forloni G, et al, (2015) Comparative magnetic resonance imaging and histopathological correlates in two SOD1 transgenic mouse models of amyotrophic lateral sclerosis. PLoS One 10: e0132159.
15. Carri MT, Grignaschi G, Bendotti C, (2006) Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27: 267-273.
16. Casoni F, Basso M, Massignan T, Gianazza E, Cheroni C, Salmona M, et al, (2005) Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem 280 (16): 16295-16304.
17. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10: 310-323.
18. Chio A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, et al, (2010) Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 75: 619-625.
19. Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis SM, Gurney ME, (1995) Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 6: 349-362.
20. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al, (2009) Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci USA 106: 20960-20965.
21. Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al, (2010) Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One 5: e9872.
22. Cozzolino M, Ferri A, Valle C, Carri MT, (2013) Mitochondria and ALS: implications from novel genes and pathways. Mol Cell Neurosci 55: 44-49.
23. Crippa V, Sau D, Rusmini P, Boncoraglio A, Onesto E, Bolzoni E, et al, (2010) The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet 19: 3440-3456.
24. Deng HX, Bigio EH, Zhai H, Fecto F, Ajroud K, Shi Y, et al, (2011) Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol 68: 1057-1061.
25. Dewil M, dela Cruz VF, Van Den Bosch L, Robberecht W, (2007) Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death. Neurobiol Dis 26: 332-341.
26. Dibaj P, Steffens H, Zschuntzsch J, Nadrigny F, Schomburg ED, Kirchhoff F, Neusch C, (2011) In vivo imaging reveals distinct inflammatory activity of CNS microglia versus PNS macrophages in a mouse model for ALS. PLoS One 6: e17910.
27. Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Boncompagni S, et al, (2008) Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 8: 425-436.
28. Dupuis L, Loeffler JP, (2009) Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr Opin Pharmacol 9: 341-346.
29. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP, (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10: 75-82.
30. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al, (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68: 1440-1446.
31. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX, (1989) Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337: 476-478.
32. Fitzgerald KC, O'Reilly EJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, Ascherio A, (2014) Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol 71: 1102-1110.
33. Gaudet AD, Popovich PG, Ramer MS, (2011) Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury. J Neuroinflammation 8: 110.
34. Ghezzi P, Bonetto V, (2003) Redox proteomics: identification of oxidatively modified proteins. Proteomics 3: 1145-1153.
35. Gill A, Kidd J, Vieira F, Thompson K, Perrin S, (2009) No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 4: e6489.
36. Gould TW, Buss RR, Vinsant S, Prevette D, Sun W, Knudson CM, et al, (2006) Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 26: 8774-8786.
37. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al, (2006) ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38: 411-413.
38. Gurlo T, von Grafenstein H, (2003) Antigen-independent cross-talk between macrophages and CD8+ T cells facilitates their cooperation during target destruction. Int Immunol 15: 1063-1071.
39. Gurney ME, (1997) The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 152 (Suppl. 1): S67-73.
40. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al, (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772-1775.
41. Hanes SD, (2015) Prolyl isomerases in gene transcription. Biochim Biophys Acta 1850: 2017-2034.
42. Heiman-Patterson TD, Sher RB, Blankenhorn EA, Alexander G, Deitch JS, Kunst CB, et al, (2011) Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler 12: 79-86.
43. Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, et al, (2011) Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol 235: 104-109.
44. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al, (2014) Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 17: 664-666.
45. Joseph MS, Bilousova T, Zdunowski S, Wu ZP, Middleton B, Boudzinskaia M, et al, (2011) Transgenic mice with enhanced neuronal major histocompatibility complex class I expression recover locomotor function better after spinal cord injury. J Neurosci Res 89: 365-372.
46. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A, (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 22: 420-448.
47. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al, (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572-574.
48. Kiefer R, Kieseier BC, Stoll G, Hartung HP, (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109-127.
49. Kiselycznyk C, Holmes A, (2011) All (C57BL/6) mice are not created equal. Front Neurosci 5: 10.
50. Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CA, Vieira de Sa R, et al, (2015) C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol 78: 426-438.
51. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al, (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208.
52. Lauranzano E, Pozzi S, Pasetto L, Stucchi R, Massignan T, Paolella K, et al, (2015) Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain 138 (Pt 4): 974-991.
53. Le Ber I, De Septenville A, Millecamps S, Camuzat A, Caroppo P, Couratier P, et al, (2015) TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging 36:3116 e5-8.
54. Lee JP, Palfrey HC, Bindokas VP, Ghadge GD, Ma L, Miller RJ, Roos RP, (1999) The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 96: 3251-3256.
55. Lever TE, Gorsek A, Cox KT, O'Brien KF, Capra NF, Hough MS, Murashov AK, (2009) An animal model of oral dysphagia in amyotrophic lateral sclerosis. Dysphagia 24: 180-195.
56. Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F, (2013) Neurons as targets for T cells in the nervous system. Trends Neurosci 36: 315-324.
57. Lobsiger CS, Boillee S, Pozniak C, Khan AM, McAlonis-Downes M, Lewcock JW, Cleveland DW, (2013) C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci USA 110: E4385-4392.
58. Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L, (2012) Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 7: e40998.
59. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al, (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11: 38-45.
60. Luigetti M, Lattante S, Zollino M, Conte A, Marangi G, Del Grande A, Sabatelli M, (2011) SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid progression and concomitant novel ANG variant. Neurobiol Aging 32:1924 e15-8.
61. Magrane J, Manfredi G, (2009) Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1615-1626.
62. Mancuso R, Navarro X, (2015) Amyotrophic lateral sclerosis: current perspectives from basic research to the clinic. Prog Neurobiol 133: 1-26.
63. Mancuso R, Olivan S, Mancera P, Pasten-Zamorano A, Manzano R, Casas C, et al, (2012) Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13: 302-310.
64. Marin B, Couratier P, Arcuti S, Copetti M, Fontana A, Nicol M, et al, (2016) Stratification of ALS patients' survival: a population-based study. J Neurol 263: 100-111.
65. Marino M, Papa S, Crippa V, Nardo G, Peviani M, Cheroni C, et al, (2015) Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol Aging 36: 492-504.
66. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al, (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465: 223-226.
67. Massignan T, Casoni F, Basso M, Stefanazzi P, Biasini E, Tortarolo M, et al, (2007) Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun 353: 719-725.
68. McGoldrick P, Joyce PI, Fisher EM, Greensmith L, (2013) Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1832: 1421-1436.
69. Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, et al, (2008) CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. J Neurosci 28: 11488-11499.
70. Mitsumoto H, Brooks BR, Silani V, (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 13: 1127-1138.
71. Mori MA, Liu M, Bezy O, Almind K, Shapiro H, Kasif S, Kahn CR, (2010) A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease. Diabetes 59: 2960-2971.
72. Nardo G, Pozzi S, Mantovani S, Garbelli S, Marinou K, Basso M, et al, (2009) Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal 11: 1559-1567.
73. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al, (2011) Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One 6: e25545.
74. Nardo G, Iennaco R, Fusi N, Heath PR, Marino M, Trolese MC, et al, (2013) Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain 136 (Pt 11): 3305-3332.
75. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al, (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133.
76. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al, (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75: 822-831.
77. Novarino G, Fabrizi C, Tonini R, Denti MA, Malchiodi-Albedi F, Lauro GM, et al, (2004) Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J Neurosci 24: 5322-5330.
78. Oliveira AL, Thams S, Lidman O, Piehl F, Hokfelt T, Karre K, et al, (2004) A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci USA 101: 17843-17848.
79. O'Rourke JG, Bogdanik L, Muhammad AK, Gendron TF, Kim KJ, Austin A, et al, (2015) C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88: 892-901.
80. Otero MG, Alloatti M, Cromberg LE, Almenar-Queralt A, Encalada SE, Pozo Devoto VM, et al, (2014) Fast axonal transport of the proteasome complex depends on membrane interaction and molecular motor function. J Cell Sci 127 (Pt 7): 1537-1549.
81. Perrin S, (2014) Preclinical research: make mouse studies work. Nature 507: 423-425.
82. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, et al, (2015) Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88: 902-909.
83. Pfohl SR, Halicek MT, Mitchell CS, (2015) Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J Neuromuscul Dis 2: 137-150.
84. Philips T, Rothstein JD, (2015) Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol 69:5 67 1-5 21.
85. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carri MT, Bendotti C, (2009) Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 10: 221-228.
86. Pupillo E, Messina P, Logroscino G, Beghi E, (2014) Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 75: 287-297.
87. Regal L, Vanopdenbosch L, Tilkin P, Van den Bosch L, Thijs V, Sciot R, Robberecht W, (2006) The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch Neurol 63: 262-267.
88. Renton AE, Chio A, Traynor BJ, (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17: 17-23.
89. Riboldi G, Nizzardo M, Simone C, Falcone M, Bresolin N, Comi GP, Corti S, (2011) ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog Neurobiol 95: 133-148.
90. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW, (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92: 689-693.
91. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al, (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
92. Rouaux C, Panteleeva I, Rene F, Gonzalez de Aguilar JL, Echaniz-Laguna A, et al, (2007) Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 27: 5535-5545.
93. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al, (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9: 4-15.
94. Seijffers R, Zhang J, Matthews JC, Chen A, Tamrazian E, Babaniyi O, et al, (2014) ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation. Proc Natl Acad Sci USA 111: 1622-1627.
95. Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, Kiernan MC, (2014) Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol 76: 643-657.
96. Specht CG, Schoepfer R, (2004) Deletion of multimerin-1 in alpha-synuclein-deficient mice. Genomics 83: 1176-1178.
97. Thams S, Brodin P, Plantman S, Saxelin R, Karre K, Cullheim S, (2009) Classical major histocompatibility complex class I molecules in motoneurons: new actors at the neuromuscular junction. J Neurosci 29: 13503-13515.
98. Turner BJ, Talbot K, (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85: 94-134.
99. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al, (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323: 1208-1211.
100. Williams KL, Solski JA, Nicholson GA, Blair IP, (2012) Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 33:1488 e15-16.
101. Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH, (2015) Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS Mice. Neuron 87: 355-370.
102. Yanamadala V, Friedlander RM, (2010) Complement in neuroprotection and neurodegeneration. Trends Mol Med 16: 69-76.
103. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, et al, (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29: 160-165.
104. Yip PK, Pizzasegola C, Gladman S, Biggio ML, Marino M, Jayasinghe M, et al, (2013) The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One 8: e61626.
105. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao GX, Chen WJ, Murong SX, (2009) A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10: 118-122.
106. Zurita E, Chagoyen M, Cantero M, Alonso R, Gonzalez-Neira A, Lopez-Jimenez A, et al, (2011) Genetic polymorphisms among C57BL/6 mouse inbred strains. Transgenic Res 20: 481-489.